MIRM vs XERS

Key Takeaways

• Mirum Pharmaceuticals (MIRM) generated $521 million in 2025 net product sales, driven by its rare liver disease portfolio, and guided for $630–$650 million in 2026 revenue.
• Xeris Biopharma Holdings (XERS) posted record total revenue of $292 million in 2025 and issued 2026 guidance of $375–$390 million, reflecting approximately 30% growth at the midpoint.
• Mirum commands a substantially larger market capitalization of approximately $6.9 billion, while Xeris sits near $1.4 billion, highlighting a significant scale differential.
• Xeris achieved near-breakeven net income in 2025 and delivered positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), whereas Mirum remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis but is narrowing its losses.
• Both stocks carry "Strong Buy" analyst consensus ratings, though Mirum's pipeline is notably more dense with multiple near-term catalysts expected throughout 2026.
• Xeris has demonstrated self-funding sustainability with positive adjusted EBITDA across all quarters of 2025, a milestone Mirum has not yet reached.

Introduction

Investors navigating the mid-cap biopharmaceutical space frequently encounter MIRM (Mirum Pharmaceuticals) and XERS (Xeris Biopharma Holdings) as two commercial-stage companies with growing product revenues and meaningful pipelines. While both operate within the healthcare sector, their therapeutic focus areas, scale, and financial profiles differ markedly. This stock comparison examines how these two names stack up across dimensions such as revenue growth, profitability trajectory, pipeline catalysts, and market positioning. For traders and investors evaluating relative performance and risk-reward profiles, understanding these distinctions is essential in the current market environment.

MIRM Overview and Recent Performance

MIRM (Mirum Pharmaceuticals) is a biopharmaceutical company specializing in novel therapies for rare and orphan diseases, with a particular emphasis on liver-related conditions. Its commercial portfolio is anchored by LIVMARLI (maralixibat), an IBAT (ileal bile acid transporter) inhibitor approved for cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), alongside acquired bile acid products Cholbam and Ctexli. In 2025, Mirum delivered total net product sales of $521.3 million, a 55% increase year-over-year, surpassing its own guidance range. LIVMARLI alone contributed $360 million, reflecting 69% growth.

In recent months, Mirum completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its pipeline. The company also initiated a Phase 2 study for MRM-3379 in Fragile X syndrome, received FDA Fast Track designation for that program, and secured FDA approval for a new LIVMARLI tablet formulation. Market sentiment has been buoyed by the company's four potentially registrational data readouts expected over an 18-month window. As of late July 2026, Mirum traded near $113 per share with a market capitalization of roughly $6.9 billion, reflecting a stock that has more than doubled over the trailing twelve months.

XERS Overview and Recent Performance

XERS (Xeris Biopharma Holdings) is a commercial-stage biopharmaceutical company developing and commercializing therapies for chronic endocrine and neurological conditions. Its product lineup includes Recorlev for endogenous Cushing's syndrome, Gvoke (ready-to-use liquid glucagon) for severe hypoglycemia, and Keveyis for primary periodic paralysis. In 2025, Xeris achieved record total revenue of approximately $292 million, representing 44% growth over the prior year. Recorlev was the standout performer, generating $139.3 million in net revenue — a 117% increase year-over-year — while Gvoke contributed $94.1 million.

A key milestone for Xeris in recent market activity was its emergence as a self-funding, sustainable biopharmaceutical company. The company delivered positive adjusted EBITDA in every quarter of 2025, totaling $59.4 million for the full year, and posted near-breakeven net income of $0.6 million. Looking ahead, Xeris guided for 2026 total revenue of $375–$390 million and is advancing XP-8121, a once-weekly subcutaneous injection for hypothyroidism, toward a Phase 3 clinical trial. As of late July 2026, Xeris traded near $8.32 per share with a market capitalization of approximately $1.4 billion, with a 52-week range of $4.87 to $10.08.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's highest-conviction AI-powered trading bots — selected from a universe of hundreds of available bots that collectively monitor thousands of tickers. Because market conditions shift continuously, only those bots whose strategies, timeframes, and statistical profiles align most favorably with current dynamics earn placement in this featured section. The bots span diverse trading styles — from high-frequency 5-minute agents to multi-day swing traders — and display verifiable metrics including annualized returns, Sharpe ratios, trade counts, and drawdown figures. For instance, top-performing Tickeron AI trading agents have delivered annualized returns ranging from 78% to over 290% under specific market regimes. Each bot comes with a fully transparent closed-trade log, enabling users to review every trade before committing capital. To explore which bots are currently trending and evaluate their live performance statistics, visit the Trending AI Robots page.

Head-to-Head Comparison

When comparing MIRM and XERS, the most immediate contrast is one of scale. Mirum's $521 million in 2025 revenue and $6.9 billion market cap significantly eclipse Xeris's $292 million and $1.4 billion, respectively. Mirum also offers a richer pipeline — with volixibat in two Phase 2b studies (VISTAS for PSC and VANTAGE for PBC), LIVMARLI in the Phase 3 EXPAND study, and newly acquired brelovitug — creating a catalyst-dense calendar for 2026 and 2027. Xeris, by contrast, has a leaner pipeline led chiefly by XP-8121, but compensates with commercial breadth across three distinct therapeutic areas and a more advanced profitability profile.

On the profitability front, Xeris holds a clear edge. The company generated positive adjusted EBITDA of $59.4 million in 2025 and achieved near-breakeven net income. Mirum, meanwhile, reported a net loss of $23.4 million for the same period, though this represented a dramatic improvement from the $87.9 million loss the prior year. Mirum expects to reach positive cash flow in 2027. In terms of valuation, Mirum trades at roughly 10.5 times trailing sales versus approximately 4.7 times for Xeris — reflecting the market's willingness to pay a premium for Mirum's larger revenue base, faster top-line growth, and richer pipeline narrative. Risk factors differ as well: Mirum faces binary event risk around multiple clinical readouts, while Xeris must navigate competitive pressures in the endocrine space and execute on the Phase 3 development of XP-8121.

Tickeron AI Verdict

Based on observable market data, trend consistency, and relative positioning, Tickeron's AI-driven analytical framework would likely express a modest preference for MIRM in the current environment — though this comes with important nuance. Mirum's combination of accelerating commercial momentum, a catalyst-rich 2026 pipeline, strong institutional ownership growth (507 funds reporting positions as of late 2025), and a robust balance sheet bolstered by $268.5 million in fresh capital from private placements provides a compelling risk-reward structure for growth-oriented strategies. The stock's 52-week range and sustained upward trajectory suggest consistent trend strength. That said, for traders prioritizing profitability metrics and lower valuation multiples, XERS presents a differentiated opportunity — particularly given its self-funding status and positive adjusted EBITDA record. The AI verdict is probabilistic, not absolute: Mirum's catalyst density and commercial scale give it a structural advantage for trend-following models, but Xeris's improving fundamentals and more grounded valuation could prove attractive under mean-reversion or value-oriented frameworks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations